This site requires a more recent version of Adobe Flash Player to function properly.
Go here to get Flash.
Trefis's graphical modelling tools require Flash, but here's a preview of some of the content you'll see once
Flash is enabled:
Investment Overview for Pfizer (NYSE:PFE)
Key drivers of Pfizer's value that present opportunities for upside or downside to the current Trefis price estimate for Pfizer:
Diversified Legacy Drugs & Alliances
- Revenue from Diversified Legacy Drugs & Alliances:
Pfizer sold its consumer healthcare division in 2006 to Johnson & Johnson. The current healthcare division bought as a part of Wyeth acquisition could face a similar future. The company has been reducing its focus on the segment and sold its nutrition business to Nestle in 2012. Further, the Animal Health division which has been a healthy and growing division for Pfizer, has been spun off into a different entity to make it a no-tax transaction. If further sell-offs more than offset any increase in revenues due to new alliances and generic drug growth, and revenues decline to $11.5 billion, there could be around 10% downside to our price estimate. On the other hand, there could be upside of similar order if the revenues grow to $23 billion instead.
Prevnar & Prevenar (7 & 13)
- Revenue from Prevnar & Prevenar (7 & 13):
The Prevnar franchise of vaccines constitutes nearly 10% to our price estimate. The franchise's revenues have stabilized recently amounting to $4.46 billion in 2014. We currently expect the figure to reach past $5.2 billion by the end of our forecast period. However, with drug's extension to new indications, the sales growth may exceed our expectations. If Prevnar is able to increase its revenues to $9 billion by the end of our forecast period, there could be a potential upside of nearly 5%-10% to our price estimate. If however, regulatory approvals take more time or are unfavorable, and Prevnar's revenues remain flat, it could lead to a slight downside.
Pfizer is currently the world's biggest pharmaceutical company in terms of revenues. It was founded in 1849 and went public in 2004. In October, 2009, Pfizer completed the acquisition of pharmaceutical giant Wyeth for $68 billion. The firm operates in two main segments: Bio-pharmaceutical and Diversified.
Bio-pharmaceutical includes the Primary Care, Specialty Care, Established Products, Emerging Markets and Oncology customer-focused units, which includes products that prevent and treat cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, respiratory diseases, urogenital conditions, cancer, eye disease and endocrine disorders.
Diversified includes consumer healthcare products such as pain management therapies, cough/cold/allergy remedies, dietary supplements, hemorrhoidal care and other personal care items, as well as nutrition products such as infant and toddler formula products.
The biggest contribution to the value of the stock comes from the Legacy Wyeth & Pfizer products, Alliances and income generated from the Diversified unit. This is explained by the following reasons.
Alliances & licensing arrangements to bolster market share
The vast network of alliances, licensing deals and other forms of joint partnerships that Pfizer has helps reduce R&D expenses. A strong distribution network, tie-ups and brand image due to world class drugs help revenues and increase market share.
Acquisitions to help boost growth at Pfizer
The Synbiotics deal which was completed at the end of 2010 has opened up a new area of growth in veterinary immuno-diagnostics. This market segment was valued around $750 million in 2010 and is projected to grow at a healthy pace annually. The acquisition of Ferrosan's consumer healthcare unit which was completed in December, 2011 will allow Pfizer to expand the marketing of Ferrosan’s brands through Pfizer’s global footprint and provide greater distribution and scale for certain Pfizer brands, such as Centrum and Caltrate.
Loss of patents impacting sales
In the last few years, several blockbuster drugs have lost patent exclusivity which includes Lipitor. This has not only impacted Pfizer, but the pharmaceutical industry as a whole. As a result, Pfizer and other firms will need to focus on growing areas of immunology and oncology.
Growing threat of generic products
The fast growing pharma market in emerging economies or referred to as the 'Pharmerging' economies have the capability and technical prowess to manufacture generic versions of blockbuster drugs. These generic drugs are often sold at prices that substantially cheaper then their branded counterparts, thereby severely affecting big pharma's ability to generate profits in the long run.
Lack of approval for Biosimilars by FDA
At present the Food & Drug Administration Authority (FDA) does not have a process to grant approvals for Biosimilars.
Though its hard to say when such a process would be initiated, the potential impacts would be severe for any big pharmaceutical firm, as Biologics seem to be the last bastion of long term profits for big pharma.
Globalization of healthcare reforms
Governments around the world are trying to rein in fiscal spending in order to manage their budget deficits
Since healthcare costs are one the biggest components of any national budget, it is obvious that increased healthcare legislation and reforms around the world will hurt revenues for the entire pharmaceutical sector.
How Does Trefis Modelling Work?
How do we get the historical numbers for this chart?
Trefis has a team of in-house Analysts who gather historical data from company filings and other verifiable sources. When historicals are available, we explain how we got them at the bottom of the Trefis analysis section below.
Who came up with the Trefis forecast for future years?
The Trefis team of in-house Analysts considers a variety of factors when projecting any forecast. The rationale for our projections is explained in the Trefis analysis section below.
How does my dragging the trendline on the chart impact the stock price?
- We use forecasts for business drivers to calculate forecasted Revenues and Profits for each division of the company.
- We then use forecasted Profits in a Discounted Cash Flow (DCF) model to obtain the Price Estimate for the company.
See more on: DCF Methodology
View All Help Topics